Saturday 17 October 2026 Export MGNX’s income statement to Excel — free account

MacroGenics, Inc.

In the quarter to June 2026, revenue grew 378.0%, EPS grew 154.4% and free cash flow grew 12.9%, each against the same quarter a year earlier.

3.25 0.12 −3.56%

Follow MGNX

Alert me

Market cap: $214.7M
P/E: 0.0×
Fwd P/E: −5.8×
Dividend yield: —
F-score: 3/9
Altman Z: −6.01
Beneish M: −0.22
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.13

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	1	—	—

Insider Ownership 3.39%

Capital & Financial Ratios $m

Market Cap 214.67

Revenue 183.05

Net Income (14.59)

Free Cash Flow (65.53)

Net Debt (173.30)

Current Ratio 2.96

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.83)

P/S ratio 1.13

P/B ratio 4.82

Past 5Y EPS Growth —

This Y EPS Growth (49.27%)

Next Y EPS Growth 6.89%

Next Y revenue growth (27.63%)

Next 5Y EPS Growth (20.19%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.84%

10-year low 10-year high

P/B against its own 10 years 85.00%

10-year low 10-year high

EV/Sales against its own 10 years 2.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	230	202	190	173
Receivables	10	4	13	144
Inventory	1	—	8	—
Other	—	—	—	—
	251	217	220	322

	2023	2024	2025	Q'26
Payables	6	5	5	3
ST’ Debt	—	—	—	—
Other	—	—	—	15
	56	56	43	109

Compound Annual Growth %

	10y	5y	3y
Sales	4.01%	7.35%	(0.54%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(15.88%)	(28.42%)	(26.85%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	33	—	—	—
’25	13	7	73	57	150
’24	9	11	111	19	150
’23	24	13	10	11	59
’22	11	26	42	73	152
’21	17	31	16	14	77
’20	14	20	18	53	105

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	(41)	—	—	—
’25	(47)	(47)	(30)	43	(81)
’24	(46)	(44)	60	(38)	(68)
’23	(13)	(2)	(35)	(28)	(78)
’22	(58)	(49)	(9)	29	(87)
’21	(29)	(46)	(15)	(54)	(144)
’20	(44)	(37)	(26)	(6)	(112)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	(42)	—	—	—
’25	(47)	(48)	(31)	43	(83)
’24	(47)	(45)	60	(39)	(72)
’23	(13)	(2)	(36)	(29)	(80)
’22	(59)	(50)	(10)	29	(91)
’21	(30)	(48)	(17)	(56)	(150)
’20	(45)	(37)	(26)	(9)	(118)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.58)	0.31	—	—	—
’25	(0.65)	(0.57)	0.27	(0.22)	(1.18)
’24	(0.84)	(0.89)	0.90	(0.25)	(1.07)
’23	(0.61)	0.92	0.28	(0.75)	(0.15)
’22	(1.08)	(0.67)	(0.40)	0.21	(1.95)
’21	(0.90)	(0.66)	(0.86)	(0.95)	(3.37)
’20	(0.91)	(0.94)	(0.66)	0.02	(2.47)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	14.84	14.36	11.16	7.43	4.04	15.72	2.13	4.29	2.95	0.99	Analyst estimates 2026–2028 Powerpack
	High	33.30	22.31	32.74	32.32	32.18	36.48	17.20	10.74	21.88	3.60
People
People	Employees	318	330	364	384	370	427	357	339	341	293
	Revenue/emp, $m	0.29	0.48	0.17	0.17	0.28	0.18	0.43	0.17	0.44	0.51
Income, $m
Income, $m	Revenue	92	158	60	64	105	77	152	59	150	150
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	96.58	95.14	86.00	91.80	75.91
	EBT	(59)	(20)	(171)	(152)	(130)	(202)	(120)	(9)	(66)	(75)
	EBT margin, %	(63.70)	(12.44)	(285.18)	(236.51)	(123.70)	(260.97)	(78.82)	(15.42)	(44.03)	(50.36)
	Net income	(59)	(20)	(171)	(152)	(130)	(202)	(120)	(9)	(67)	(75)
	Depreciation	8	7	8	11	12	13	12	5	5	6
Per share, $
Per share, $	Revenue	2.65	4.37	1.47	1.33	2.00	1.29	2.47	0.95	2.39	2.37
	Earnings	(1.69)	(0.54)	(4.19)	(3.16)	(2.47)	(3.37)	(1.95)	(0.15)	(1.07)	(1.18)
	Cash flow	(1.26)	0.40	(3.74)	(2.79)	(2.13)	(2.40)	(1.42)	(1.26)	(1.09)	(1.28)
	Capex	(0.33)	(0.81)	(0.61)	(0.09)	(0.11)	(0.10)	(0.06)	(0.03)	(0.06)	(0.03)
	Free cash flow	(1.59)	(0.42)	(4.35)	(2.88)	(2.25)	(2.50)	(1.47)	(1.29)	(1.15)	(1.31)
	Book value	7.75	8.29	5.93	4.80	5.64	4.00	2.31	2.46	1.85	0.88
	Shares, m	35	36	41	48	52	60	61	62	63	63
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	7.48	4.44	8.65	8.15	11.43	12.42	2.57	10.73	1.36	0.68
	P/B	2.56	2.34	2.14	2.27	4.05	4.02	2.75	4.13	1.75	1.83
	EV/Sales	4.54	2.55	4.88	4.89	8.89	9.36	1.60	6.93	0.05	(0.55)
	EV/FCF	(7.57)	(26.82)	(1.65)	(2.26)	(7.92)	(4.83)	(2.68)	(5.09)	(0.11)	0.99
Cash, $m
Cash, $m	Operating cash flow	(44)	14	(153)	(134)	(112)	(144)	(87)	(78)	(68)	(81)
	Capex	(11)	(29)	(25)	(4)	(6)	(6)	(4)	(2)	(4)	(2)
	Free cash flow	(55)	(15)	(178)	(139)	(118)	(150)	(91)	(80)	(72)	(83)
Balance, $m
Balance, $m	Working capital	257	273	209	195	262	205	174	195	162	177
	Total debt	0	—	—	31	29	25	35	—	—	—
	Net debt	(277)	(305)	(233)	(216)	(273)	(244)	(154)	(230)	(202)	(190)
	Shareholders’ equity	269	299	243	231	296	240	142	153	116	56
Returns, %
Returns, %	ROA	(17.46)	(5.73)	(48.57)	(47.10)	(37.54)	(56.62)	(38.90)	(3.13)	(23.91)	(28.78)
	ROIC	0.00	0.00	(1,068.54)	(744.62)	(350.76)	0.00	0.00	0.00	0.00	0.00
	ROE	(20.11)	(6.91)	(63.25)	(64.12)	(49.28)	(75.49)	(62.76)	(6.15)	(49.85)	(86.95)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%	Compare
PLX Protalix BioTherapeutics, Inc.	$217.5M	10.9×	10.2×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)
ALEC Alector, Inc.	$213.3M	— (loss-making)	— (loss-making)	−57.84% (below 0%: shrinking)	n/m	+30.19% (above 0%: growing)	100.00%	(734.73%)	Compare
IFRX InflaRx N.V.	$212.2M	— (loss-making)	— (loss-making)	−128.93% (below 0%: shrinking)	n/m	+69.33% (above 0%: growing)	14,029.95%	0.00%	Compare
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$215.2M	—	—	−57.84%	—	+8.16%	100.00%	0.00%

All 614 Biotechnology stocks →

MacroGenics, Inc. (MGNX) key facts

Concern: MacroGenics, Inc. reported a net loss of $74.6 million, or a loss of $1.18 per share, for fiscal 2025.
MacroGenics, Inc. (MGNX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MGNX traded at $3.25, a market capitalization of $214.7 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.1× sales.
Return on equity was −87.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −6.01 (distress zone) for fiscal 2025.